AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for LAWRENCE B. PALMER
+0.03 (0.73%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.11 - 4.30
52 week 2.96 - 11.65
Open 4.28
Vol / Avg. 404,320.00/602,172.00
Mkt cap 183.55M
P/E     -
Div/yield     -
EPS -0.77
Shares 44.34M
Beta 2.21
Inst. own 80%
Aug 10, 2015
Q2 2015 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 24, 2015
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
Jun 24, 2015
AcelRx Pharmaceuticals Inc at JMP Securities Life Sciences Conference - Webcast
Jun 23, 2015
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting
Jun 1, 2015
AcelRx Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 18, 2015
AcelRx Pharmaceuticals Inc at UBS Global Healthcare Conference
May 12, 2015
AcelRx Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2015
AcelRx Pharmaceuticals Inc at Mizuho Securities Healthcare Corporate Access Day
May 4, 2015
Q1 2015 AcelRx Pharmaceuticals Inc Earnings Call
May 4, 2015
Q1 2015 AcelRx Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -5539.23% -639.31%
Operating margin -6298.34% -721.66%
EBITD margin - -705.06%
Return on average assets -49.64% -33.95%
Return on average equity -91.67% -55.67%
Employees 50 -
CDP Score - -


351 Galveston Drive
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 49
Bio & Compensation  - Reuters
Howard B. Rosen Interim Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 57
Bio & Compensation  - Reuters